BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs developed for the rapid and complete reversal of neuromuscular blockade induced by rocuronium and vecuronium. Many studies have demonstrated a close-response relationship with sugammadex for reversal of neuromuscular blockade in patients induced and maintained under propofol anesthesia. However, sevoflurane anesthesia, unlike propofol, can prolong the effect of neuromuscular blocking drugs (NMBDs) such as rocuronium and vecuronium.METHODS: We designed this randomized, open-label, dose-response trial to explore the dose-response relationship of sugammadex for the reversal of deep neuromuscular blockade induced by rocuronium or vecuronium under propo...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Contains fulltext : 51845.pdf (publisher's version ) (Closed access)BACKGROUND: Re...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
peer reviewedBackground: Sugammadex rapidly reverses rocuronium-induced neuromuscular block. This st...
Sugammadex shows a dose-response relationship for reversal of neuromuscular block (NMB) during propo...
BACKGROUND: Reversal of rocuronium-induced neuromuscular blockade can be accomplished by chemical en...
BACKGROUND AND OBJECTIVE: Sugammadex, a modified gamma-cyclodextrin, is a selective relaxant-binding...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Contains fulltext : 51845.pdf (publisher's version ) (Closed access)BACKGROUND: Re...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
BACKGROUND: Sugammadex is the first of a new class of selective muscle relaxant binding drugs develo...
peer reviewedBackground: Sugammadex rapidly reverses rocuronium-induced neuromuscular block. This st...
Sugammadex shows a dose-response relationship for reversal of neuromuscular block (NMB) during propo...
BACKGROUND: Reversal of rocuronium-induced neuromuscular blockade can be accomplished by chemical en...
BACKGROUND AND OBJECTIVE: Sugammadex, a modified gamma-cyclodextrin, is a selective relaxant-binding...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Contains fulltext : 51845.pdf (publisher's version ) (Closed access)BACKGROUND: Re...